Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages 406-412

  Sinicrope, Frank A ^a   Foster, Nathan R ^a   Yoon, Harry H ^a   Smyrk, Thomas C ^a   Kim, George P ^c   Allegra, Carmen J ^d,f   Yothers, Greg ^e,f   Nikcevich, Daniel A ^a,b   Sargent, Daniel J ^a  

^a North Central Cancer Treatment Group Rochester   (United States)

^b Duluth Community Clinical Oncology Program   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ARTICLE; BODY MASS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OBESITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856699420     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.2563     Document Type: Article

References (59)

1. Poynter JN, Siegmund KD, Weisenberger DJ, et al: Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17:3208-3215, 2008
2. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993 (Pubitemid 23167612)
3. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875, 1998 (Pubitemid 28278073)
4. Hampel H, Frankel WL, Martin E, et al: Screening for the Lynch syndrome (hereditary non-polyposis colorectal cancer). N Engl J Med 352:1851-1860, 2005
5. Jass JR, Do KA, Simms LA, et al: Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42:673-679, 1998 (Pubitemid 28261055)
6. Samowitz WS, Curtin K, Ma KN, et al: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10:917-923, 2001 (Pubitemid 32844897)
7. Alexander J, Watanabe T, Wu TT, et al: Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158:527-535, 2001 (Pubitemid 32158613)
8. Greenson JK, Bonner JD, Ben-Yzhak O, et al: Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 27:563-570, 2003 (Pubitemid 36514468)
9. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875, 2011
10. Lanza G, Gafà R, Santini A, et al: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24:2359-2367, 2006
11. Halling KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999 (Pubitemid 29387571)
12. Gafà R, Maestri I, Matteuzzi M, et al: Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89:2025-2037, 2000
13. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 (Pubitemid 46224239)
14. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 (Pubitemid 36859476)
15. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
16. Jover R, Nguyen TP, Pérez-Carbonell L, et al: 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140:1174-1181, 2011
17. Campbell PT, Jacobs ET, Ulrich CM, et al: Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 102:391-400, 2010
18. Slattery ML, Curtin K, Anderson K, et al: Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 92:1831-1836, 2000
19. Limsui D, Vierkant RA, Tillmans LS, et al: Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 102:1012-1022, 2010
20. Larsson SC, Wolk A: Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies. Am J Clin Nutr 86:556-565, 2007 (Pubitemid 47435820)
21. Pischon T, Lahmann PH, Boeing H, et al: Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98:920-931, 2006 (Pubitemid 44018922)
22. Giovannucci E, Ascherio A, Rimm EB, et al: Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 122:327-334, 1995
23. Le Marchand L, Wilkens LR, Kolonel LN, et al: Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 57:4787-4794, 1997 (Pubitemid 27468985)
24. Martínez ME, Giovannucci E, Spiegelman D, et al: Leisure-time physical activity, body size, and colon cancer in women: Nurses' Health Study Research Group. J Natl Cancer Inst 89:948-955, 1997 (Pubitemid 27282067)
25. Ford ES: Body mass index and colon cancer in a national sample of adult US men and women. Am J Epidemiol 150:390-398, 1999
26. Sinicrope FA, Foster NR, Sargent DJ, et al: Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res 16:1884-1893, 2010
27. Meyerhardt JA, Catalano PJ, Haller DG, et al: Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 98:484-495, 2003 (Pubitemid 36885987)
28. Dignam JJ, Polite BN, Yothers G, et al: Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 98:1647-1654, 2006 (Pubitemid 44811647)
29. Kirschner MA, Schneider G, Ertel NH, et al: Obesity, androgens, estrogens, and cancer risk. Cancer Res 42:3281s-3285s, 1982 (Pubitemid 12022708)
30. Slattery ML, Potter JD, Curtin K, et al: Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 61:126-130, 2001 (Pubitemid 32095709)
31. Flegal KM, Carroll MD, Ogden CL, et al: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288:1723-1727, 2002
32. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation to Obesity (WHO Technical Report Series 894). Geneva, Switzerland, 1998
33. Hedley AA, Ogden CL, Johnson CL, et al: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291:2847-2850, 2004 (Pubitemid 38747805)
34. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil: The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7:1447-1456, 1989 (Pubitemid 19245114)
35. [No authors listed]: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
36. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990 (Pubitemid 20042739)
37. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997 (Pubitemid 27020580)
38. Beart RW Jr, Moertel CG, Wieand HS, et al: Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion: A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 125: 897-901, 1990 (Pubitemid 20218807)
39. Wiesenfeld M, O'Connell MJ, Wieand HS, et al: Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 13:2324-2329, 1995
40. O'Connell MJ, Sargent DJ, Windschitl HE, et al: Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer 6:133-139, 2006 (Pubitemid 44445748)
41. Kim GP, Colangelo LH, Wieand HS, et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772, 2007 (Pubitemid 350002875)
42. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
43. Zubrod CG, Schneiderman MA, Frei E, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis 11:7-33, 1960
44. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001 (Pubitemid 32319494)
45. Boland CR, Thibodeau SN, Hamilton SR, et al: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248-5257, 1998
46. Thibodeau SN, French AJ, Roche PC, et al: Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 56:4836- 4840, 1996
47. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
48. Lengauer C, Kinzler KW, Vogelstein B: Genetic instability in colorectal cancers. Nature 386:623-627, 1997 (Pubitemid 27175430)
49. Campbell PT, Cotterchio M, Dicks E, et al: Excess body weight and colorectal cancer risk in Canada: Associations in subgroups of clinically defined familial risk of cancer. Cancer Epidemiol Biomarkers Prev 16:1735-1744, 2007 (Pubitemid 47450502)
50. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96:8681-8686, 1999 (Pubitemid 29354851)
51. Nosho K, Shima K, Irahara N, et al: SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 22:922-932, 2009
52. Hursting SD, Berger NA: Energy balance, host-related factors, and cancer progression. J Clin Oncol 28:4058-4065, 2010
53. Hautanen A: Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 24:S64-S70, 2000 (suppl 2)
54. Schneider G, Kirschner MA, Berkowitz R, et al: Increased estrogen production in obese men. J Clin Endocrinol Metab 48:633-638, 1979 (Pubitemid 9167803)
55. Meyerhardt JA, Niedzwiecki D, Hollis D, et al: Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and Leukemia Group B 89803. J Clin Oncol 26:4109-4115, 2008
56. Rondini EA, Harvey AE, Steibel JP, et al: Energy balance modulates colon tumor growth: Interactive roles of insulin and estrogen. Mol Carcinog 50:370-382, 2011
57. Yakar S, Nunez NP, Pennisi P, et al: Increased tumor growth in mice with diet-induced obesity: Impact of ovarian hormones. Endocrinology 147:5826-5834, 2006 (Pubitemid 44833499)
58. Renehan AG, Roberts DL, Dive C: Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem 114:71-83, 2008 (Pubitemid 351998746)
59. Sinicrope FA, Dannenberg AJ: Obesity and breast cancer prognosis: Weight of the evidence. J Clin Oncol 29:4-7, 2011